Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesScinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.454 USD 0.01 ( 2.95%)
Last update at 2026-11-09T15:34:00Z
VOLUME
11067
Market Cap
1.16M
P/E
0.06

Momentum Score

…

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.44
Low
0.45
High
52 Week Price Range
1.50
Low
16.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) are limited; available filings identify it as a biotechnology company focused on immunotherapeutic research. Long-term growth may be supported by advances in the immunotherapy market, successful commercialization or licensing of any developed candidates, and strategic partnerships, which could support value creation for investors.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.44
Dividend Yield
-
Revenue TTM
1.49M
Revenue Per Share
2.80
Gross Profit TTM
-3.75M
Debt / Equity
0.28
ROE
-26.53%
Net Debt
0.61M
ROCE
-79.16%
Diluted EPS TTM
28.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.31M 4.80M -6.50M -5.80M -39.98M
Net income -8.31M 4.80M -6.50M -5.80M -39.98M
Selling general administrative 2.52M 2.53M 4.50M 5.30M 23.98M
Gross profit -2.65M -0.58M -0.51M - -
Reconciled depreciation 1.42M 1.65M 0.51M 0.56M 2.42M
Ebit -7.95M -8.64M -2.70M -11.06M -34.86M
Ebitda -6.53M -6.99M -2.19M -10.50M -32.44M
Depreciation and amortization 1.42M 1.65M 0.51M 0.56M 2.42M
Operating income -7.54M -8.64M -9.71M -11.06M -34.83M
Other operating expenses 8.85M 9.30M 9.71M 11.06M 34.83M
Interest expense 0.36M 1.44M 3.80M - 10.83M
Interest income 0.02M 0.10M 0.12M 5.26M 0.00M
Net interest income -0.35M -1.33M 0.12M 5.26M -10.86M
Income tax expense - - 0.00M - 10.83M
Total revenue 1.31M 0.66M 0.00M 0.00M 0.00M
Total operating expenses 4.89M 8.06M 9.71M 11.06M 34.83M
Cost of revenue 3.96M 1.24M 0.51M - -
Total other income expense net -0.77M 13.43M 3.21M 5.26M 5.71M
Net income from continuing ops -8.31M 4.80M -6.50M -5.80M -39.98M
Net income applicable to common shares - - - -5.80M -8.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.63M 13.45M 17.47M 27.07M 99.60M
Other current assets 0.23M - - 0.14M 0.14M
Total liab 3.52M 3.47M 22.04M 28.83M 76.27M
Total stockholder equity 8.10M 9.98M -4.57M -1.76M 23.33M
Other current liab 0.76M - 0.85M 1.24M 3.33M
Capital stock 5.63M 5.63M 0.00M 0.00M 0.00M
Retained earnings -125.85M -117.54M -122.33M -115.83M -364.77M
Other liab - - - 5.33M -
Cash 1.66M 1.96M 4.87M 14.07M 54.04M
Total current liabilities 1.58M 1.81M 1.78M 2.34M 7.21M
Current deferred revenue 0.09M - - - -
Net debt 0.61M - 15.69M 7.47M 15.70M
Short term debt 0.33M - 0.40M 0.38M 0.77M
Short long term debt total 2.27M - 20.56M 21.54M 69.74M
Other stockholder equity 130.06M - 119.51M 116.08M 388.10M
Property plant equipment - - - 12.70M 14.19M
Total current assets 2.05M 2.39M 5.45M 14.37M 55.05M
Net tangible assets - - - -1.76M 0.98M
Net receivables 0.17M 0.08M 0.37M 0.11M 0.31M
Long term debt 0.29M 0.26M 19.37M 20.08M 63.25M
Accounts payable 0.41M 0.38M 0.54M 0.72M 3.11M
Accumulated other comprehensive income -1.74M - -1.74M -2.01M -
Non currrent assets other - - - - 0.44M
Non current assets total 9.57M 11.06M 12.03M 12.70M 44.55M
Capital lease obligations 1.97M 1.83M 1.19M 1.46M 6.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01M -0.64M -0.84M -0.36M
Change to liabilities - - - -0.17M 0.00M
Total cashflows from investing activities -0.02M -0.01M -0.64M -0.84M -0.14M
Total cash from financing activities 5.77M 3.44M 1.09M 6.78M 67.78M
Change to operating activities - - - 0.31M 0.64M
Net income -8.31M 4.80M -6.50M -5.80M -39.98M
Change in cash -0.28M -2.92M -9.21M -3.30M 44.62M
Begin period cash flow 2.10M 5.01M 14.21M 17.52M 9.42M
End period cash flow 1.81M 2.10M 5.01M 14.21M 54.04M
Total cash from operating activities -6.03M -6.33M -9.38M -7.26M -24.48M
Issuance of capital stock 5.77M 2.00M 0.14M 0.93M 69.00M
Depreciation 1.42M 1.65M 0.51M 0.56M 2.42M
Change to account receivables 0.05M 0.14M -0.29M 0.14M 0.06M
Other cashflows from financing activities - 1.44M 0.95M 5.84M -0.36M
Change to netincome - - - -2.30M -0.40M
Capital expenditures 0.02M 0.01M 0.64M 0.84M 0.43M
Change in working capital 0.16M 0.11M -0.65M 0.27M 5.18M
Stock based compensation 0.30M 0.68M 1.14M 1.60M 8.90M
Other non cash items 0.39M -13.57M -3.89M -3.90M -1.00M
Free cash flow -6.05M -6.35M -10.02M -8.10M -24.91M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SCNI
Scinai Immunotherapeutics Ltd		 0.01
2.95%		 0.45 0.06 - 0.78 0.19 5.18 1.13
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

Jerusalem BioPark, Jerusalem, Israel

972 8 930 2529

https://www.scinai.com

45

Name Title Year Born
Mr. Amir Reichman M.B.A., M.Sc. CEO & Director 1976
Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer 1982
Dr. Tamar Ben-Yedidia Ph.D. Chief Science Officer 1964
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA Chief Financial Officer 1970
Ms. Dalit Weinstein Fischer Chief Technology Officer NA
Mr. Joshua E. Phillipson B.Sc., M.B.A. Director of Communications & Investor Relations NA
Liat Halpert Head of Business Development & Sales NA
Ms. Moran Ahdout Fruchter L.L.B. Chief of Staff NA
Merav Kamensky Head of Quality Control NA
Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…